Graves' Disease

Smith, Terry J; Hegedüs, Laszlo

Published in:
The New England Journal of Medicine

DOI:
10.1056/NEJMra1510030

Publication date:
2016

Document version:
Final published version

Document license:
Unspecified

Citation for published version (APA):

Terms of use
This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

• You may download this work for personal use only.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk

Download date: 04. Apr. 2022
Graves’ Disease

Terry J. Smith, M.D., and Laszlo Hegedüs, M.D., D.M.Sc.

GRAVES’ DISEASE WAS FIRST RECOGNIZED IN THE 19TH CENTURY AS A syndrome comprising an enlarged and overactive thyroid gland, an accelerated heart rate, and ocular abnormalities (Fig. 1). Critical for our current understanding of this disease was the discovery of its autoimmune basis, which results from complex interactions between genetic and environmental factors.1,2 Graves’ disease has adverse effects on quality of life,3 as a consequence of somatic4 and psychiatric5 symptoms and an inability to work,6 and is associated with an increased risk of death.7 Activating thyrotropin-receptor antibodies induce thyroid hormone overproduction. Many characteristic signs and symptoms of Graves’ disease result from elevated thyroid hormone levels. Debate persists concerning the diagnosis of hyperthyroidism and adequate clinical care of affected patients.8,9 Thyroid-associated ophthalmopathy (Fig. 1B), the most common and serious extrathyroidal manifestation, results from underlying autoimmunity, but insights into its pathogenesis and care remain elusive.

Epidemiology

Graves’ disease is the most common cause of hyperthyroidism, with an annual incidence of 20 to 50 cases per 100,000 persons.10 The incidence peaks between 30 and 50 years of age, but people can be affected at any age. The lifetime risk is 3% for women and 0.5% for men. Long-term variations in iodine intake do not influence the risk of disease, but rapid repletion can transiently increase the incidence. The annual incidence of Graves’ disease–associated ophthalmopathy is 16 cases per 100,000 women and 3 cases per 100,000 men. It is more common in whites than in Asians.11 Severe ophthalmopathy is more likely to develop in older men than in younger persons.12 Orbital imaging reveals subtle abnormalities in 70% of patients with Graves’ disease.13 In specialized centers, clinically consequential ophthalmopathy is detected in up to 50% of patients with Graves’ disease, and it threatens sight as a consequence of corneal breakdown or optic neuropathy in 3 to 5% of such patients.14 Hyperthyroidism and ophthalmopathy typically occur within 1 year of each other but can be separated by decades. In 10% of persons with ophthalmopathy, either thyroid levels remain normal or autoimmune hypothyroidism develops.12,14

Clinical Presentation

Hyperthyroidism

The manifestations of Graves’ disease depend on the age of the patient at the onset of hyperthyroidism, as well as the severity and the duration of hyperthyroidism.15 Symptoms and signs result from hyperthyroidism (goiter in some cases) or are a consequence of underlying autoimmunity (Table 1). Weight loss, fatigue, heat
Graves’ Disease

intolerance, tremor, and palpitations are the most common symptoms, occurring in more than 50% of patients. Weight loss, decreased appetite, and cardiac manifestations are more common in elderly persons with hyperthyroidism than in those who are younger. Atrial fibrillation due to hyperthyroidism is rare in patients who are younger than 60 years of age but occurs in more than 10% of patients who are 60 years of age or older. Pulpable goiter develops in most patients with hyperthyroidism who are younger than 60 years of age (Fig. 1A), as compared with less than 50% of older patients. Diffuse thyroid enlargement is most frequent, but many patients with Graves’ disease who live in iodine-deficient regions have coexisting nodular goiter.

Figure 1. Clinical Manifestations of Graves’ Disease.
Panel A shows a diffuse, moderately enlarged goiter in a woman with Graves’ hyperthyroidism. Panel B shows moderate-to-severe, thyroid-associated ophthalmopathy characterized by bilateral proptosis, periorbital edema, scleral injection, and lid retraction. Panel C shows the plaque form of pretibial dermopathy. Panel D shows acropachy with clubbing of the fingers.
Thyroid-Associated Ophthalmopathy

Orbital involvement represents a parallel consequence of the underlying autoimmunity occurring within the thyroid. Ophthalmopathy can be disfiguring and can threaten sight. Its clinical course typically follows a pattern originally described by Rundle and Wilson. Disease development is heralded by an active phase lasting up to 3 years and dominated by evolving symptoms and signs of inflammation and congestion. Proptosis (Fig. 1B), eyelid swelling, and diplopia may prompt initial medical attention. Some patients have dry eye, increased tearing, and ocular discomfort early in the active phase. This is followed by an inactive phase in which the ocular manifestations become stable. Table 1 lists the most common features of ophthalmopathy. In a cohort of consecutively assessed patients with Graves’ disease, the prevalence of distinct abnormalities was as follows: eyelid retraction, 92%; exophthalmos, 62%; extraocular muscle dysfunction, 43%; ocular pain, 30%; increased lacrimation, 23%; and optic neuropathy, 6%.19

Mild eyelid retraction or lag may occur in thyrotoxicosis from any cause, as a result of increased sympathetic tone. The activity of ophthalmopathy can be graded by assigning 1 point for each of the following manifestations: eyelid erythema and edema, conjunctiva injection, caruncular swelling, chemosis, retrobulbar pain, and pain with eye movement. A score of 3 or higher indicates active disease. The activity score — together with an evaluation of the severity of symptoms, including proptosis, reduced visual acuity, and impaired eye movement — guides treatment decisions.20

*Table 1. Major Symptoms and Physical Signs in Graves’ Disease.*

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Physical signs of hyperthyroidism</th>
<th>Extrathyroidal physical signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight loss (weight gain in 10% of patients)</td>
<td>Tachycardia, atrial fibrillation</td>
<td>Ophthalmopathy</td>
</tr>
<tr>
<td>Palpitations</td>
<td>Systolic hypertension, increased pulse pressure</td>
<td>Eyelid lag, retraction, or both</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>Cardiac failure</td>
<td>Proptosis (exophthalmos)</td>
</tr>
<tr>
<td>Tremor</td>
<td>Weight loss</td>
<td>Double vision (extraocular-muscle dysfunction)</td>
</tr>
<tr>
<td>Tiredness, fatigue, muscle weakness</td>
<td>Fine tremor, hyperkinesis, hyperreflexia</td>
<td>Periorbital edema, chemosis, scleral injection</td>
</tr>
<tr>
<td>Heat intolerance, increased sweating</td>
<td>Warm, moist skin</td>
<td>Exposure keratitis</td>
</tr>
<tr>
<td>Increased stool frequency</td>
<td>Palmar erythema and onycholysis</td>
<td>Optic neuropathy</td>
</tr>
<tr>
<td>Anxiety, altered mood, insomnia</td>
<td>Muscle weakness</td>
<td>Localized dermopathy</td>
</tr>
<tr>
<td>Nervousness, hyperactivity</td>
<td>Hair loss</td>
<td>Acropachy</td>
</tr>
<tr>
<td>Pruritus</td>
<td>Diffuse, palpable goiter and thyroid bruit</td>
<td></td>
</tr>
<tr>
<td>Thirst and polyuria</td>
<td>Mental-status and mood changes (e.g., mania or depression)</td>
<td></td>
</tr>
<tr>
<td>Menstrual disturbances in women (oligomenorrhea or amenorrhea)</td>
<td>Ophthalmopathy</td>
<td>Ophthalmopathy</td>
</tr>
<tr>
<td>Loss of libido</td>
<td>Localized dermopathy</td>
<td>Localized dermopathy</td>
</tr>
<tr>
<td>Neck fullness</td>
<td>Acropachy</td>
<td>Acropachy</td>
</tr>
</tbody>
</table>
| Eye symptoms (swelling, pain, redness, double vision) | Thyroid dermopathy (Fig. 1C) occurs in 1 to 4% of patients with Graves’ disease and is nearly always seen in those with severe ophthalmopathy.21 It most frequently localizes to the pretibial region but can occur elsewhere, especially after trauma to the skin. Acropachy resembles clubbing of the fingers or toes and occurs only in patients with dermopathy21 (Fig. 1D).

**Pathogenesis**

**Initiating Factors**

Unambiguous identification of the factors underlying Graves’ disease has not yet been accomplished. Genetic and epigenetic determinants are leading candidates for these factors.1,2,22 Large-scale genetic analyses have identified several genes conferring susceptibility. These include genes encoding thyroglobulin, thyrotropin receptor, HLA-DRβ-Arg74, the protein tyrosine phosphatase nonreceptor type 22 (PTPN22), cytotoxic
ANTI–THYROTROPIN-RECEPTOR ANTIBODIES
Activating autoantibodies of the IgG1 subclass that are directed against the thyrotropin receptor are both specific for and central to Graves' disease (Fig. 2A). Their oligoclonal generation, primarily by intrathyroidal B cells, reflects the disease's primary autoimmune reaction. These antibodies stimulate thyroid hormone production that is uncontrolled by the hypothalamic–pituitary axis. Activating antibodies mimic the actions of thyrotropin at its receptor through the initiation of similar, but not identical, signaling. How these diverse factors interact to confer a risk of disease remains uncertain.

T CELLS AND B CELLS
Both T cells and B cells, critical components of adaptive immunity, are necessary for the development of Graves' disease. Thymic education of immune cells leads to the deletion of autoreactive T cells from the lymphocyte pool. These T cells show proliferative responses through antigen-specific interactions occurring between T-cell receptors and major-histocompatibility-complex (MHC) molecules on antigen-presenting cells such as dendritic cells, monocytes, and B cells. T cells rely on second signals, without which they become anergic. Some T cells differentiate into effector-cell phenotypes that have the functions of type 1, type 2, or type 17 helper T cells (Th1, Th2, or Th17). Others develop into regulatory T cells (e.g., regulatory T cells with the CD25+Foxp3+ phenotype), which can attenuate immune reactivity. Each phenotype produces a characteristic pattern of cytokines. The balance between proinflammatory factors and factors that dampen immune reactivity determines the amplitude and duration of immune responses.

Thyroid Epithelial-Cell Involvement
The precise role (or roles) of thyroid epithelial cells in the pathogenesis of Graves' disease remains incompletely understood. These cells express important organ-specific antigens, such as the thyrotropin receptor, thyroglobulin, and...
Theoretical Model of Intrathyroidal Graves’ Disease

thyroperoxidase. Thyroid epithelial cells release several chemokines and thus may participate in the recruitment of these and other immune cells. In Graves’ disease, thyroid epithelial cells also express MHC class II molecules, probably as a consequence of infiltrating, lymphocyte-produced interferon-γ action in situ. Thus, although thyroid epithelial cells are not considered professional antigen-presenting cells, they have the potential to present thyroid antigens to T cells. In addition, their CD40 expression suggests the potential for direct, productive interactions between thyroid epithelium and antigen-specific T cells in Graves’ disease. The aggregate of cur-
trated with lymphocytes; their phenotypes and active disease, orbital tissues are variably infiltrated by B and T cells and antigen-presenting cells produce interleukins 1β, 6, and 12; interferon-γ; tumor necrosis factor α; CD40 ligand; and other cytokines. These cytokines, in turn, activate and sustain inflammation and alter the behavior of thyroid epithelial cells. Antithyroid drugs can attenuate the production of thyroid hormones and the expression of intrathyroidal cytokines and thus modulate the autoimmune process. Panel B shows a theoretical model of the pathogenesis of thyroid-associated ophthalmopathy. The orbit becomes infiltrated by B and T cells and CD34+ fibrocytes. The bone marrow–derived fibrocytes differentiate into CD34+ fibroblasts, which can further differentiate into myofibroblasts or adipocytes. CD34+ fibroblasts coinhabit the orbit with residential CD34− fibroblasts. These cells can all produce cytokines, depending on the molecular signals they encounter in the microenvironment. These include interleukins 1β, 6, 8, and 16; tumor necrosis factor α (TNF-α); RANTES (regulated on activation, normal T-cell expressed and secreted); and CD40 ligand. These cytokines, in turn, activate orbital fibroblasts. The CD34+ fibroblasts express low levels of thyrotropin receptor, thyroglobulin, and other thyroid antigens. Thyroid-stimulating immunoglobulins activate the thyrotropin–insulin-like growth factor 1 (IGF-1) receptor complex, leading to the expression of inflammatory molecules and glycosaminoglycan synthesis. In addition, immunoglobulins directed against the IGF-1 receptor can activate signaling in orbital fibroblasts, leading to cytokine and hyaluronan production. Cytokine-activated fibroblasts synthesize hyaluronan and other glycosaminoglycans, which expand orbital tissue and cause proptosis and optic-nerve compression. In addition, the orbital fat expands, probably as a consequence of adipogenesis. MHC denotes major histocompatibility complex, and TGF-β transforming growth factor β.

Figure 2 (facing page). Pathogenesis of Graves' Disease Affecting the Thyroid Gland and Orbit.

Panel A shows a theoretical model of the pathogenesis of intrathyroidal Graves' disease. Thyroid-stimulating immunoglobulins provoke the overproduction of thyroid hormones by activating the thyrotropin receptor, thus abrogating the normal regulatory role of thyrotropin. In addition, infiltrating immune cells such as B and T cells and antigen-presenting cells produce interleukins 1β, 6, and 12; interferon-γ; tumor necrosis factor α; CD40 ligand; and other cytokines. These cytokines, in turn, activate and sustain inflammation and alter the behavior of thyroid epithelial cells. Antithyroid drugs can attenuate the production of thyroid hormones and the expression of intrathyroidal cytokines and thus modulate the autoimmune process. Panel B shows a theoretical model of the pathogenesis of thyroid-associated ophthalmopathy. The orbit becomes infiltrated by B and T cells and CD34+ fibrocytes. The bone marrow–derived fibrocytes differentiate into CD34+ fibroblasts, which can further differentiate into myofibroblasts or adipocytes. CD34+ fibroblasts coinhabit the orbit with residential CD34− fibroblasts. These cells can all produce cytokines, depending on the molecular signals they encounter in the microenvironment. These include interleukins 1β, 6, 8, and 16; tumor necrosis factor α (TNF-α); RANTES (regulated on activation, normal T-cell expressed and secreted); and CD40 ligand. These cytokines, in turn, activate orbital fibroblasts. The CD34+ fibroblasts express low levels of thyrotropin receptor, thyroglobulin, and other thyroid antigens. Thyroid-stimulating immunoglobulins activate the thyrotropin–insulin-like growth factor 1 (IGF-1) receptor complex, leading to the expression of inflammatory molecules and glycosaminoglycan synthesis. In addition, immunoglobulins directed against the IGF-1 receptor can activate signaling in orbital fibroblasts, leading to cytokine and hyaluronan production. Cytokine-activated fibroblasts synthesize hyaluronan and other glycosaminoglycans, which expand orbital tissue and cause proptosis and optic-nerve compression. In addition, the orbital fat expands, probably as a consequence of adipogenesis. MHC denotes major histocompatibility complex, and TGF-β transforming growth factor β.

Extraocular Manifestations

In Graves' disease, the immune pathogenesis of ophthalmopathy and that of hyperthyroidism are presumed to be similar. The orbital process primarily targets fibroblasts (Fig. 2B). During active disease, orbital tissues are variably infiltrated with lymphocytes; their phenotypes and variable-region gene use have been partially characterized.37 Interactions between T cells and fibroblasts result in tissue activation and induction of genes involved in inflammation and tissue remodeling.38 These events are mediated by several cytokines, including interleukin-1β, interleukin-6, and CD40 ligand. Orbital fat and extraocular muscles expand from accumulating hyaluronidase-digestible material and adipogenesis.12 Extraocular muscles remain intact, but fibers become widely separated. In later stages of the disease, extraocular muscles can become fibrotic, resulting in restricted motility. It remains uncertain what provokes lymphocyte infiltration, but a shared antigen in the orbit and thyroid gland, such as the thyrotropin receptor, seems likely.12 This view is supported by the relatively low level of expression in orbital fat and orbital fibroblasts.12,39,40 Fibroblasts inhabiting the orbit in Graves' disease are heterogeneous, and when activated by cytokines, they produce hyaluronan and several inflammatory mediators. Fibroblasts that display CD34, CXCR4, and collagen 1 are apparently derived from circulating fibrocytes,40,41 which are monocyte-lineage progenitor cells with inflammatory characteristics. The unique presence of fibrocytes in the orbit in ophthalmopathy suggests that they play a part in disease development. Fibrocytes promiscuously express proteins previously thought to be restricted to the thyroid. These include thyrotropin receptor, thyroglobulin, thyroperoxidase, and sodium–iodide symporter, the expression of which is driven by the autoimmune regulator protein.41,42 Moreover, fibrocytes efficiently present antigens to T cells. When activated by thyrotropin or thyroid-stimulating immunoglobulins, fibrocytes release cytokines that have been implicated in Graves' disease. Fibrocytes can differentiate into adipocytes or myofibroblasts and thus might contribute to the tissue remodeling in ophthalmopathy.

Involvement of the insulin-like growth factor 1 receptor in ophthalmopathy is suggested by its overexpression by orbital fibroblasts, T cells, and B cells in Graves' disease.28,43,44 Furthermore, serum antibodies against this receptor can be detected in some persons with the disease, although the interpretation of this finding remains controversial. A functional and physical relationship between the insulin-like growth factor 1 receptor and the thyrotropin receptor has been...
interrupting the insulin-like growth factor 1 receptor attenuates signaling downstream from the thyrotropin receptor, an observation that has subsequently been confirmed.

Mechanisms involved in pretibial myxedema are even less well understood. The lesions are infiltrated with hyaluronan and are typically not inflammatory.

The diagnosis of hyperthyroidism is based on characteristic clinical features and biochemical abnormalities. Figure 3 shows a commonly used diagnostic algorithm, which is a sufficient tool for most cases. If pathognomonic features such
as ophthalmopathy or dermopathy are absent and a diffuse goiter is not detected, radionuclide scanning can confirm the diagnosis. These scanning studies and radioiodine uptake measurement can be used to distinguish Graves’ disease from other causes of thyrotoxicosis. Routine measurement of thyrotropin-receptor antibodies is not mandatory, but when such assays are performed, they have 99% sensitivity and specificity for Graves’ disease.47 They are also helpful in diagnosing Graves’ disease in patients with concomitant nodular goiter.17 Assays that can routinely distinguish anti–thyrotropin-receptor antibodies that stimulate thyroid hormone production from those that block thyroid hormone production are under development.48

THYROID-ASSOCIATED OPHTHALMOPATHY
Computed tomography or magnetic resonance imaging of the orbit is warranted when the cause of ocular manifestations remains uncertain. These imaging studies are useful in distinguishing extraocular muscle enlargement from fat expansion. Especially in cases of asymmetric proptosis, ruling out orbital tumor and arteriovenous malformation is important. Assessment of the activity and severity of ophthalmopathy, which can usually be accomplished by clinical examination, helps guide therapy.49 Several other imaging techniques, including orbital ultrasonography, scintigraphy with radiolabeled octreotide, gallium scanning, and thermal imaging, may be useful in more precisely defining the orbital disease.50

ANTITHYROID DRUGS
Methimazole, carbimazole (which is converted to methimazole and is not available in the United States), and propylthiouracil inhibit thyroid peroxidase and thus block thyroid hormone synthesis (Table 2). Propylthiouracil also blocks extrathyroidal deiodination of thyroxine to triiodothyronine. Methimazole is preferred for initial therapy in both Europe and North America because of its favorable side-effect profile.5,52 Both methimazole and propylthiouracil are associated with a high risk of recurrence after treatment has been withdrawn. Several variables appear to be associated with durable disease remission, defined as biochemical euthyroidism for at least 12 months, after 1 to 2 years of therapy (Table 2). Durable remission occurs in 40 to 50% of patients. Repeated therapy carries an even lower likelihood of success. It remains uncertain whether remission results from immunomodulation by these drugs. The recurrence rate is not further decreased by providing treatment for more than 18 months or by combining antithyroid drugs with levothyroxine. Patients may be switched from one drug to another when necessitated by minor side effects, but 30 to 50% of patients have a similar reaction to each drug.55 In our opinion, patients with severe side effects should not be further exposed to either drug. Monitoring by means of liver-function tests and white-cell counts before and during antithyroid drug therapy is advocated by some experts but is not currently supported by consensus opinion.8,9,55 One randomized study showed no benefit from granulo-
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Mode of Action</th>
<th>Route of Administration</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Special Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta-blockers</td>
<td>Beta-blockers competitively block β-adrenergic receptors; propranolol may block conversion of thyroxine to triiodothyronine</td>
<td>Oral; may be administered intravenously in acute cases</td>
<td>Ameliorates sweating, anxiety, tremulousness, palpitations, and tachycardia</td>
<td>Does not influence course of disease; use cautiously in patients with asthma, congestive heart failure, bradyarrhythmias, or Raynaud’s phenomenon</td>
<td>Use cardioselective beta-blockers, especially in patients with COPD; use calcium-channel blockers as alternative</td>
</tr>
<tr>
<td>Antithyroid drugs (methimazole, carbimazole, and propylthiouracil)</td>
<td>Methimazole, carbimazole, and propylthiouracil block thyroid peroxidase and thyroid hormone synthesis; propylthiouracil also blocks conversion of thyroxine to triiodothyronine</td>
<td>Given as either a single, high fixed dose (e.g., 10–30 mg of methimazole or 200–600 mg of propylthiouracil daily) and adjusted as euthyroidism is achieved or combined with thyroxine to prevent hypothyroidism (&quot;block–replace&quot; regimen)</td>
<td>Outpatient therapy; low risk of hypothyroidism; no radiation hazard or surgical risk; remission rate, 40–50%†</td>
<td>High recurrence rate; frequent testing required unless block-replacement therapy is used; minor side effects in ≤5% of patients (rash, urticaria, arthralgia, fever, nausea, abnormalities of taste and smell)</td>
<td>Major side effects in 0.2–0.3% of patients, usually within first 3 mo of therapy; agranulocytosis in &lt;0.2% of patients; heptotoxicity in ≤0.1%; cholestatic for the thionamides and hepatocellular necrosis for propylthiouracil; antineutrophil cytoplasmic antibody–associated vasculitis in ≤0.1% of patients</td>
</tr>
<tr>
<td>Radioactive iodine (iodine-131)</td>
<td>Irradiation causes thyroid cell damage and cell death</td>
<td>Oral; activity either fixed (e.g., 15 mCi [555 MBq]) or calculated on the basis of goiter size and uptake and turnover investigations</td>
<td>Normally outpatient procedure, definitive therapy, low cost, few side effects, effectively reduces goiter size</td>
<td>Potential radiation hazards, adherence to a country’s particular radiation regulations, radiation thyroiditis, decreasing efficacy with increasing goiter size, eventual hypothyroidism in most patients</td>
<td>Should not be used in patients with active thyroid ophthalmopathy; contraindicated in women who are pregnant or breast-feeding and for 6 wk after breast-feeding has stopped</td>
</tr>
</tbody>
</table>
| Thyroidectomy                   | Most or all thyroid tissue is removed surgically                                | Rapid euthyroidism, recurrence extremely rare,‡ no radiation hazard, definitive histologic results, rapid relief of pressure symptoms | Most expensive therapy, hypothyroidism is the aim, risks associated with surgery and anesthesia, minor complications in 1–2% of patients (bleeding, infection, scarring), major complications in 1–4% (hypoparathyroidism, recurrent laryngeal nerve damage) | Does not influence course of Graves’ ophthalmopathy, during pregnancy, is best performed during the second trimester§ | * COPD denotes chronic obstructive pulmonary disease. † The following factors are associated with an increased risk of recurrence after antithyroid drug therapy: previous recurrence of Graves’ disease, cigarette smoking, ophthalmopathy, large goiter, elevated ratio of serum free triiodothyronine to free thyroxine, high titers of serum anti-thyrotropin-receptor antibodies, and persistent need for high-dose antithyroid drugs after 12 to 18 months of treatment. In the absence of these risk factors, euthyroidism is generally sustained for at least 12 months after therapy has been withdrawn. § The risks of hypothyroidism and persistent or recurrent hyperthyroidism are related to the volume of residual thyroid tissue.
cyte colony-stimulating factor in patients with agranulocytosis.64

Radioactive Iodine
Radioactive iodine therapy has been used widely in patients with Graves’ disease for seven decades.65 It offers relief from symptoms of hyperthyroidism within weeks. Treatment with antithyroid drugs may be suspended 3 to 7 days before and after radiotherapy in order to enhance its efficacy, although this interval remains controversial.66 Many clinicians use fixed doses of radioiodine, since calculation of activity is costly and fails to reduce rates of hypothyroidism or recurrent hyperthyroidism.69 Radioiodine is not associated with an increased risk of cancer67 but is known to provoke or worsen ophthalmopathy.14 Instead, increased morbidity and mortality associated with Graves’ disease appear to be related to hyperthyroidism itself.65 Postablation thyroid function should be monitored throughout life, and if hypothyroidism develops, it should be treated immediately.

Surgery
Before patients undergo surgical thyroidectomy, their thyroid hormone levels should be normal to minimize the risk of complications or a poor outcome, which is higher for total thyroidectomy than for subtotal thyroidectomy. The risks of hypothyroidism and recurrent hyperthyroidism are inversely related and depend on the volume of residual tissue.68,69 Treatment with inorganic iodide commencing 1 week before surgery may decrease thyroid blood flow, vascularity, and blood loss but does not otherwise influence surgical risk.70 Surgery may be an attractive option for patients with large goiters, women wishing to become pregnant shortly after treatment, and patients who want to avoid exposure to antithyroid drugs or radioiodine. It is recommended that women who have undergone surgery wait until the serum thyrotropin level stabilizes with levothyroxine therapy before attempting conception. The course of ophthalmopathy appears to be unaffected by surgical thyroidectomy.68,71

Treatment during Pregnancy
Graves’ disease affects approximately 0.1% of pregnancies and carries a substantial risk of adverse effects in mother and child, especially if it is inadequately treated.72 The lowest effective dose of an antithyroid drug should be used to maintain thyroid function at the upper limit of the normal range in order to avoid fetal hypothyroidism. Both propylthiouracil and methimazole are associated with birth defects.57 The use of propylthiouracil in the first trimester and methimazole during the remainder of pregnancy is currently recommended on the basis of a consideration of potentially severe birth defects.73 Thyroid function should be monitored monthly. In up to 50% of cases, antithyroid drugs may be discontinued after the first trimester, but postpartum relapse is common.72 If elevated by a factor of more than 3, the level of anti–thyrotropin-receptor antibodies, beginning at a gestational age of 18 to 24 weeks, identifies pregnancies at risk for neonatal hyperthyroidism.72 Breast-feeding is safe with either methimazole or propylthiouracil, but methimazole is recommended for postpartum therapy and does not affect infant thyroid function in the doses commonly used.74,75

Ophthalmopathy
Treatment for ophthalmopathy depends on the phase and severity of the disease. The majority of patients require only conservative measures (Table 3). These include enhancement of tear-film quality and maintenance of ocular surface moisture. Patients with disease that is severely symptomatic and sight-threatening may benefit from intravenously administered pulse glucocorticoid therapy, which appears to have a more favorable side-effect profile than glucocorticoids administered orally, although pulse therapy is not without risks.50,61,76 Glucocorticoids are frequently effective in reducing inflammatory symptoms, but most experts do not believe that they modify the course of the disease. External-beam irradiation of severely affected orbits is used in some specialized centers but not others.77 The combination of glucocorticoids and radiotherapy may provide a greater benefit than either treatment used alone.62 Orbital decompression surgery during active disease is usually reserved for patients in whom compressive optic neuropathy has developed or is imminent.78 Decompression surgery is also indicated when the ocular surface is severely compromised. These situations constitute surgical emergencies. Rituximab, a biologic agent that depletes CD20+ B cells, has been evaluated recently in two prospective, randomized pilot studies involving patients with active, severe
Table 3. Treatments for Thyroid-Associated Ophthalmopathy.

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Mode of Action</th>
<th>Pros and Cons</th>
<th>Common Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild active disease</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topical solutions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artificial tears</td>
<td>Maintain tear film</td>
<td>Rapid action, minimal side effects</td>
<td></td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Reduce inflammation</td>
<td>Rapid action, minimal side effects</td>
<td></td>
</tr>
<tr>
<td>Avoidance of wind, light, dust, smoke</td>
<td>Reduces ocular surface desiccation, reduces irritation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elevation of head during sleep</td>
<td>Reduces orbital congestion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avoidance of eye cosmetics</td>
<td>Reduces irritation</td>
<td>Benefits not yet confirmed</td>
<td></td>
</tr>
<tr>
<td>Selenium⁹</td>
<td>Uncertain</td>
<td>Benefits not yet confirmed</td>
<td></td>
</tr>
<tr>
<td><strong>Moderate or severe active disease</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic glucocorticoids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td>Reduce inflammation and orbital congestion</td>
<td>Hyperglycemia, hypertension, osteoporosis</td>
<td>Up to 100 mg of oral prednisone daily, followed by tapering of the dose⁶⁰</td>
</tr>
<tr>
<td>Intravenous</td>
<td>Reduce inflammation and orbital congestion</td>
<td>Rapid onset of anti-inflammatory effect, fewer side effects than oral delivery, liver damage on rare occasions</td>
<td>Methylprednisolone, 500 mg/wk for 6 wk followed by 250 mg/wk for 6 wk⁶¹,⁶²</td>
</tr>
<tr>
<td>Orbital irradiation</td>
<td>Reduces inflammation</td>
<td>Can induce retinopathy</td>
<td>2 Gy daily for 2 wk (20 Gy total)⁶³</td>
</tr>
<tr>
<td>B-cell depletion*</td>
<td>Reduces autoreactive B cells</td>
<td>Very expensive; risks of infection, cancer, allergic reaction</td>
<td>Two 1000-mg doses of intravenous rituximab 2 wk apart</td>
</tr>
<tr>
<td><strong>Stable disease (inactive)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orbital decompression (fat removal)</td>
<td>Reduces orbital volume</td>
<td>Postoperative diplopia, pain</td>
<td></td>
</tr>
<tr>
<td>Bony decompression of the lateral and medial walls</td>
<td>Reduces proptosis by enlarging orbital space</td>
<td>Postoperative diplopia, pain, sinus bleeding, cerebrospinal fluid leak</td>
<td></td>
</tr>
<tr>
<td>Strabismus repair</td>
<td>Improves eye alignment, reduces diplopia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eyelid repair</td>
<td>Improves appearance, reduces lagophthalmos, and improves function</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* B-cell depletion with the use of rituximab is currently considered an experimental treatment for ophthalmopathy; rituximab is not approved by the Food and Drug Administration for this indication.
† Emergency orbital decompression is indicated for optic neuropathy or severe corneal exposure.

ophthalmopathy. One trial suggested efficacy,⁷⁹ whereas the other did not.⁸⁰

Therapy during the stable phase of moderate-to-severe ophthalmopathy usually involves rehabilitative surgery aimed at reducing proptosis, restoring function, and enhancing appearance. The procedures are usually performed in a set sequence, beginning with orbital decompression. Multiple approaches to surgical decompression have been perfected, but controlled studies of their relative efficacies have not been performed.⁸¹ The decision about which approach should be used depends on the primary objective of the surgery and the skill of the surgeon.⁷⁸ In patients with diplopia, surgical decompression is followed by strabismus surgery to correct abnormalities of eye motility.⁸² Cosmetic and functional concerns are addressed last, with facelifts, tissue fillers, and eyelid repair. Most assessments of therapy for Graves’ hyper-

The New England Journal of Medicine
Downloaded from nejm.org at UNIV LIBRARY OF SOUTHERN DENMARK on September 8, 2017. For personal use only. No other uses without permission.
Copyright © 2016 Massachusetts Medical Society. All rights reserved.
thyroidism suggest that radioactive iodine ablation increases the risk of new or worsening ophthalmopathy. Glucocorticoids appear to mitigate this risk. In contrast, most studies have failed to detect differences in the effect on ophthalmopathy between surgical thyroidectomy and medical therapy.

**DERMATOPATHY AND ACROPAHY**

Topical glucocorticoids can be used for symptomatic and extensive dermopathy but are usually ineffective. The observation of a striking improvement in dermopathy after rituximab infusion suggests that B-cell depletion may benefit affected patients. However, this treatment is experimental and has not been approved by the Food and Drug Administration. No specific therapy is available for acropachy.

**FUTURE THERAPIES**

As we gain a clearer understanding of Graves' disease, the potential for “smart drug” development increases. Repurposing agents that effectively disrupt cytokine networks in rheumatoid arthritis appears to be an attractive approach, but controlled, prospective trials are necessary. Agents blocking the thyrotropin and insulin-like growth factor receptors are under consideration. For example, a randomized, placebo-controlled clinical trial of the efficacy and safety of teprotumumab, an insulin-like growth factor 1 receptor–blocking monoclonal antibody, in patients with active, severe ophthalmopathy has recently been completed (ClinicalTrials.gov number, NCT01868997). Graves' disease appears to be an ideal candidate for antigen-specific therapy, since the identity of a dominant self-antigen is known. Restoring immune tolerance to the thyrotropin receptor and other relevant autoantigens remains the ultimate goal, sparing patients nonspecific immunosuppression and toxic drugs.

---

**REFERENCES**

Epigenetic profiling in CD4+ and CD8+ T cells from Graves’ disease patients reveals changes in genes associated with T cell receptor signaling. J Autoimmun 2016;67: 46-56.


30. Rapoport B, McLachlan SM. Graves’ hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease. J Clin Endocrinol Metab 2014;99:4060-1.


GRAVES’ DISEASE


Copyright © 2016 Massachusetts Medical Society.